Popular Articles
Stretch Mark Cream

World Food Programme Commends G8 Leaders' Focus On Food Security; Urges Support For Hunger Needs Of World's Poorest
As leaders at the G8 summit in L"Aquila gather to discuss global
generic viagra online
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression In Rheumatoid Arthritis Models By Selective Inhibition Of The Immunoproteasome
Proteolix, Inc. announced that in an article published in Nature Medicine, Proteolix"s selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the highest dose. The anti-inflammatory effect induced by PR-957 was rapid and long-lasting, lowering expression of multiple inflammatory mediators, including TNF-a and IL-6. Disease regression was evident 24 hours after dosing and a complete amelioration of disease was achieved with a single dose. When compared to anti-TNF-a therapy (etanercept), PR-957 mediated a more rapid resolution of clinical symptoms, including joint inflammation, and was more effective than etanercept in a model of aggressive arthritis. Drugshop to buy zoloft online and other pills.
News of the day
Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R
Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases.
Cardiovascular

One In Four HIV-Positive Women Does Not Undergo Cervical Cancer Screenings, Study Finds

About one in four HIV-positive women in the U.S. does not opt to undergo an annual Pap test for cervical cancer even though they are at an increased risk for the disease, according to a study in the Journal of Acquired Immune Deficiency Syndromes, Reuters reports. For the study, Alexandra Oster and colleagues from the Centers for Disease Control and Prevention analyzed the responses of 2,417 HIV-positive women from 18 states who participated in interviews for the Supplement to HIV/AIDS Surveillance Project.The researchers found that 23% of the women had not undergone a Pap test in the year before the interviews and that older age and a poorly functioning immune system were independent predictors of whether women had Pap tests.They wrote, "The risk of cervical cancer has not decreased since the introduction of (highly active antiretroviral) therapy, highlighting the continued importance of cervical cancer screening in this population." They added that "cervical cancer screening should be a high priority" for HIV-positive women (Reuters, 7/30). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):